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Question:  After ordering a type and screen I was notified by the blood bank that my patient has 
cold autoantibodies. Does this mean that my patient has a cold agglutinin disease?  
 
 
Answer:  Many patients have antibodies in 
their plasma which bind to antigens present 
on the surface of their own red blood cells.  
Commonly, these autoantibodies are easily 
detectable in the laboratory at cold 
temperatures (4° C) but may be very weak 
or undetectable when the samples are 
warmed to body temperature (37° C). While 
cold autoantibodies are generally not 
clinically significant and do not cause 
hemolysis in the patient, they may delay 
serologic testing of the blood. 
Autoantibodies can obscure the 
identification of underlying clinically 
significant alloantibodies, requiring 
additional testing to find appropriate 
crossmatch compatible units for transfusion.  
Although the majority of cold 
autoantibodies are benign, they may rarely 
be associated with hemolysis.  
Cold agglutinin disease (CAD) is a 
rare type of autoimmune hemolytic anemia 
caused by cold autoantibodies. The 
autoantibodies found in CAD differ from the 
commonly encountered cold autoantibodies.  
They are often present at an extremely high 
titer (≥ 1:1000 at 4° C) and also demonstrate 
a high thermal amplitude, making them 
easily detectable at temperatures above 30° 
C.  Blood samples in the laboratory may 
spontaneously agglutinate, and the 
peripheral smear shows clumps of 
agglutinated red blood cells (Figure 1).   
 
 
Figure 1.  Peripheral smear demonstrating red blood 
cell agglutination due to cold agglutinin disease. 
 
The direct antiglobulin test (DAT) is 
positive for complement (C3) and negative 
for IgG. The autoantibodies in CAD are of 
the IgM type and usually have specificity for 
the I or i carbohydrate antigens on the red 
blood cell surface, although autoantibody 
specificity alone is not diagnostic of CAD. 
These IgM antibodies bind to the red blood 
cells as they pass through lower 
temperatures in the peripheral circulation.  
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Components of complement then attach to 
the red blood cells before the IgM 
dissociates as the red blood cells return to 
warmer temperatures. Serologic testing in 
the blood bank can detect cold 
autoantibodies in these patients; however the 
presence of hemolysis must be confirmed 
with additional laboratory results such as 
hemoglobin, hematocrit, reticulocyte count, 
bilirubin, haptoglobin and LDH.   
Patients with CAD can be divided 
into acute and chronic disease.  The acute 
type occurs most often in younger patients.  
Hemolysis in these patients is self-limited 
and is often associated with infections with 
organisms such as Mycoplasma pneumoniae 
or the Epstein-Barr virus.  Chronic CAD is 
typically seen in elderly patients with 
underlying lymphoproliferative disorders.  If 
a transfusion is required for either acute or 
chronic CAD, a blood warmer must be used.  
In summary, most cold 
autoantibodies detected in the blood bank 
are not clinically significant and do not point 
to a diagnosis of CAD.  If the cold 
autoantibody has both a high titer and a high 
thermal amplitude, the patient should be 
evaluated for signs of hemolysis due to cold 
agglutinin disease.   
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